(Reuters) -Biogen Inc said on Wednesday a European Medicines Agency panel has voted against the marketing application for its Alzheimer’s disease drug, sending shares of the drugmaker down 3%.
The panel, Committee for Medicinal Products for Human Use, will adopt a final opinion at a December meeting, the company said.
The U.S. approval for the drug, aducanumab, has drawn criticism from scientists, who are doubting whether the clinical evidence proves that the treatment works.
(Reporting by Manas Mishra in Bengaluru; Editing by Krishna Chandra Eluri and Anil D’Silva)
